Search clinical trials for: SP2086

Total 61 results

Jiangsu HengRui Medicine Co., Ltd.

Unknown

The Pharmacokinetics and Pharmacodynamics Study of Single and Multiple Dose of SP2086 in Type 2 Diabetes Patients

Type 2 Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

The Pharmacokinetics Study of Single and Multiple Dose of SP2086 in Healthy Volunteers

Type 2 Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

The Metabolite Identification and Material Balance Study of SP2086

Type 2 Diabetes
Jiangsu HengRui Medicine Co., Ltd.

Completed

SP2086 Pharmacokinetic Study in Renal Insufficiency Patients

Renal Insufficiency
Jiangsu HengRui Medicine Co., Ltd.

Unknown

Efficacy and Safety of SP2086 as Monotherapy in Patients With Type 2 Diabetes

Type 2 Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

the Food Effect Pharmacokinetic, Material Balance and Metabolite Identification of SP2086 in Healthy Volunteers

Type 2 Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

The Drug-drug Interaction of SHR3824 and SP2086

Type 2 Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

Efficacy and Safety Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes

Type 2 Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Unknown

A Phase III Study of SP2086 in Combination With Metformin in Patients With Type 2 Diabetes

Type 2 Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

The Drug-drug Interaction of SP2086 and Metformin

Type 2 Diabetes
Jiangsu HengRui Medicine Co., Ltd.

Completed

A Study of the Effectiveness and Safety of SP2086 to Treat Type 2 Diabetes

Type 2 Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

The Drug -Drug Interaction of SP2086 and Glyburide

Type 2 Diabetes

China
Spero Therapeutics
United States Department of Defense

Completed

Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function

Renal Impairment

New Zealand
Pfizer

Completed

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to Gardasil and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 11 and 17

Vaccines | Meningococcal Vaccines

United States
Novan, Inc.
Premier Research Group plc

Completed

A Study to Evaluate the Safety and Efficacy of SB206 in Subjects With Molluscum Contagiosum

Molluscum Contagiosum

United States
Leadiant Biosciences, Inc.

Completed

STP206 for the Prevention of Necrotizing Enterocolitis (NEC)

Necrotizing Enterocolitis

United States
Small Pharma Ltd

Completed

IM and IV SPL026 Drug Product in Healthy Participants

Major Depressive Disorder

United Kingdom
Pfizer

Completed

A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age

Vaccines | Meningococcal Vaccines

United States
Bristol-Myers Squibb

Completed

A Study of BMS-562086 in Patients With Irritable Bowel Syndrome

Irritable Bowel Syndrome

United States
Novan, Inc.

Completed

SB208 for the Treatment of Tinea Pedis

Tinea Pedis

Dominican Republic
Leadiant Biosciences, Inc.

Completed

Safety and Tolerability of STP206 in Healthy Adult Subjects

Healthy

United States
Pfizer

Completed

Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose

Meningococcal Infection

United States, Finland, Czechia, Sweden, Denmark, Germany
Novan, Inc.
Synteract, Inc.; Therapeutics, Inc.

Completed

A Phase 3 Molluscum Contagiosum Efficacy and Safety Study (B-SIMPLE4)

Molluscum Contagiosum

United States
Spero Therapeutics
United States Department of Defense

Completed

Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers

Healthy Volunteers

United Kingdom
Pfizer

Completed

Study To Describe The Safety, Tolerability, And Immunogenicity Of Bivalent Rlp2086 Vaccine In Laboratory Workers ≥18 To ≤65 Years Of Age (B1971042)

Meningitis, Meningococcal, Serogroup B

United States
Pfizer

Completed

Study Evaluating Safety & Immunogenicity of rLP2086 Vaccine in Adolescents

Healthy

Australia
Eisai Inc.

Completed

A Study To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E2086 in Healthy Adult and Elderly Participants

Healthy Volunteers

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating the Safety, Immunogenicity and Tolerability of Meningococcal Group B Vaccine in Healthy Adults

Meningitis, Meningococcal

Australia
Spero Therapeutics
Clinical Network Services (CNS) Pty Ltd

Completed

A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Healthy Volunteers

Healthy Volunteers

Australia
Pfizer

Completed

A Global Phase 3 Safety Study of 120 mcg rLP2086 Vaccine in Adolescents and Young Adults Aged 10 to 25 Years

Meningitis, Meningococcal

United States, Australia, Spain, Chile, Finland, Denmark, Estonia, Czech Republic, Germany, Lithuania, Poland, Sweden
Jiangsu HengRui Medicine Co., Ltd.

Unknown

The DDI Study of SP2086 and Valsartan

Type 2 Diabetes

China
Pfizer

Completed

A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years.

Meningitis | Meningococcal Vaccine | rLP2086 | Repevax | N Meningitidis Serogroup B

Germany, Finland, Poland
Jiangsu HengRui Medicine Co., Ltd.

Completed

The Drug-drug Interaction of SP2086 and Simvastatin

Type 2 Diabetes

China
Jiangsu HengRui Medicine Co., Ltd.

Completed

The Drug-drug Interaction of SP2086 and Valsartan

Type 2 Diabetes

China
Pfizer

Completed

A Trial to Assess the Lot Consistency, Safety, Tolerability and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Subjects Aged ≥10 to <19 Years

Meningococcal Vaccine

United States, Canada, Finland, Italy, Poland, United Kingdom, Czech Republic, Germany
Jiangsu HengRui Medicine Co., Ltd.

Unknown

The DDI Study of SP2086 and Simvastatin

Type 2 Diabetes

China
Pfizer

Completed

A Trial to Assess the Safety, Tolerability, and Immunogenicity of Bivalent rLP2086 Vaccine When Given to Healthy Young Adults Aged >=18 to <26 Years. (B1971016)

Healthy

Spain, United States, Finland, Canada, Denmark, Poland
Pfizer

Completed

A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age.

Meningococcal Vaccine

United States, Finland, Czechia, Poland
Sandoz
Sandoz GmbH

Completed

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Neulasta® (PROTECT-1)

Breast Neoplasms | Chemotherapeutic Toxicity | Chemotherapy-induced Neutropenia | Neutropenic Complications

Russian Federation, Brazil, India, Mexico, Romania, Ukraine
Sandoz
Sandoz GmbH

Completed

Phase III Study Comparing the Efficacy and Safety of LA-EP2006 and Peg-Filgrastim (PROTECT2)

Breast Cancer | Chemotherapy-induced Neutropenia

Spain, United States, Argentina, Chile, India, Malaysia, Puerto Rico, Russian Federation
Novan, Inc.
Synteract, Inc.

Completed

A Phase 3 Efficacy & Safety of SB206 & Vehicle Gel for the Treatment of MC (B-SIMPLE2)

Molluscum Contagiosum

United States
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Safety And Blood Collection Study Of Meningococcal B Rlp2086 Vaccine In Adults

Meningitis, Meningococcal

Australia
Novan, Inc.
Synteract, Inc.

Completed

A Phase 3 Randomized Parallel Group Study Comparing the Efficacy & Safety of SB206 & Vehicle Gel in the Treatment of MC (B-SIMPLE1)

Molluscum Contagiosum

United States
National Institute of Mental Health (NIMH)

Completed

PET Imaging of Brain mGluR5 Receptors Using [18F]SP203

Healthy | PET Scan | Glutamate Receptor | mGlur5 Protein | Excitatory Amino Acid Receptors | Drug Kinetics

United States
Novan, Inc.
PPD

Completed

Topical NVN1000 for the Treatment of External Genital and Perianal Warts

Genital Warts | Perianal Warts

United States
Sandoz

Completed

Phase III Study Comparing the Efficacy and Safety of EP2006 and Filgrastim (PIONEER)

Breast Cancer | Chemotherapy Associated Neutropenia

Czech Republic, Hungary, Latvia, Russian Federation, Slovakia, Ukraine
Pfizer

Completed

Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers.

Meningococcal B Disease

Australia, Poland, Finland, Czechia
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose of Meningococcal Polysaccharide Diphtheria Toxoid Conjugate Vaccine (SP284) in Japanese Subjects

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Japan
Small Pharma Ltd

Completed

SPL026 (DMT Fumarate) in Healthy Subjects and MDD Patients

Major Depressive Disorder

United Kingdom
Pfizer

Completed

Study Evaluating Safety And Tolerability Of Meningococcal B Rlp2086 Vaccine In Healthy Adults

Meningitis, Meningococcal

United States

3

Subscribe